We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Magnetic Nanoparticles Detect Cancerous Cells in Breast Tissue Samples

By Labmedica staff writers
Posted on 10 Mar 2008
A new medical device based on biomagnetics will make the early detection of breast cancer more cost-effective and easier to administer. More...
Consisting of magnetic nanoparticles and an extremely sensitive magnetometer, it will detect cancerous cells in samples of breast tissue.

By automating the process through which cancerous cells are detected and quantified, the new device, which is called HistoMag, will not only ease the pressure on pathologists but also help to identify the 15-30% of patients who are likely to benefit from being treated with the drug Herceptin.

A team of scientists from University College London (UCL; UK) developed HistoMag. "At UCL we [have] been working in the relatively new area of biomagnetics to develop a technique that provides more quantitative and reliable results, whilst also enabling pathologists to identify abnormal tissue sections much more quickly,” said Prof. Quentin Pankhurst of the London Center for Nanotechnology (LCN, London, UK) and the UCL department of physics and astronomy.

"Cancerous cells have a protein on their surface called HER2. We use a solution of HER2 antibodies, tagged with magnetic nanoparticles, to stain the tissue sample. Using the HistoMag we can detect the quantity of tagged antibodies which attach themselves to the HER2 protein, which in turn provides us with an accurate picture of the spread of cancerous cells” Prof. Pankhurst added.

According to Prof. Pankhurst, pathologists have had to stain tissue samples with brown dyes to help them determine whether they are normal or cancerous. The main problem with this is that all of the results are open to interpretation, and each test has to be individually checked by a specialist.

The team at UCL, led by Prof. Pankhurst, is one of seven groups to receive a Brian Mercer Feasibility Award from the Royal Society this year. The UK£25,000 award will enable the team to reengineer the HistoMag, increasing its sensitivity before it goes on to clinical trials. The goal is to make the device generally available to pathologists in 2010.


Related Links:
University College London
London Center for Nanotechnology

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.